Skip to main content

Milestone 1.A

Enable precision medicine research by supporting deep and longitudinal molecular endophenotyping of existing and new at-risk cohorts as well cohorts and/or individuals who resist disease despite high genetic risk (e.g. Down Syndrome, ApoE 4 homozygous, FAD mutation carriers). Ensure that these efforts include and prioritize molecular profiling in cohorts from special populations and patients with atypical AD and ADRD (Down Syndrome, early- and late-onset familial AD, early-onset non-autosomal dominant AD), ethnic minorities and other under-represented groups.


Success Criteria

Initiate at least 6 research programs to support:

  • Longitudinal as well as postmortem collection and rapid distribution of biosamples from brain and peripheral tissues in existing and newly launched cohorts across diverse population groups.
  • Generation of high-quality, multi-omic data (genomic, epigenomic, proteomic, metabolomics, microbiome) as a public/community resource to maximize data accessibility and usability for downstream analyses.
  • Collection of non-traditional data modalities to complement the rich phenotypic clinical and molecular data, using wearable sensors and mobile health technologies
  • High-quality data curation, annotation and data storage/big data infrastructure to ensure that the data are made broadly and rapidly available as a public resource according to FAIR data standards.


Research Implementation Area
Population Studies and Precision Medicine
Timeline
2016–2023
Status
In Progress

Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations